CeMines Biologics, LLC company is working on more accurate, simple blood tests to diagnose lung, breast, prostate, and other cancers. The firm's CeMines Molecular FingerPrinting technology uses biostatistics to determine if disease biomarkers found in a patient's blood sample indicate the likelihood of cancer. Its lead product candidate, CeMines CellCorrect LAb, detects patterns of key antibodies that indicate cancer cells are present. Noted researcher Toomas Neuman, whose use of stem cells to treat Parkinson's disease triggered a national debate, founded the company in 2000 with several other officers of the company, which is led by CEO Richard Cavalli.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson’s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company’s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.

Adamis Pharmaceuticals Corporation company was founded in 2006 and is based in Del Mar, California. Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company. The Company’s wholly owned subsidiary, Biosyn, Inc. has a portfolio of product candidates known as microbicides. Biosyn’s product candidates, which include both contraceptive and non-contraceptive microbicides, are used intravaginally. Biosyn’s product candidates include Savvy, which underwent Phase III clinical trials in Ghana and Nigeria for reduction in the transmission of human immunodeficiency virus/acquired immunodeficiency disease, (HIV/AIDS). Effective April 1, 2009, Cellegy Pharmaceuticals, Inc. merged with Adamis Pharmaceuticals Corporation, pursuant to which Adamis Pharmaceuticals Corporation (Adamis) became a wholly owned subsidiary of the Company.

Sucampo Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland. Sucampo Pharmaceuticals, Inc., through its subsidiaries, focuses on the discovery, development, and commercialization of drugs based on prostones in the United States, Europe, and Japan. It offers prostone-based compounds for the treatment of gastrointestinal, vascular, respiratory, and central nervous system diseases and disorders. The company primarily markets Amitiza for the treatment of chronic idiopathic constipation in adults, as well as for irritable bowel syndrome with constipation in adult women. It also offers Rescula (unoprostone isopropyl) for the treatment of glaucoma. In addition, Sucampo Pharmaceuticals is conducting two Phase III pivotal trials of Amitiza for opioid-induced bowel dysfunction; a Phase II proof of concept trial of Cobiprostone for the prevention of non-steroidal anti-inflammatory drug induced ulcers; various preclinical trials of Cobiprostone for cystic fibrosis respiratory symptoms, topical ulcers and wounds, and chronic obstructive pulmonary disease; and a preclinical phase study of SPI-017 for Alzheimer's disease. The company also has various pre-clinical studies of six additional preclinical prostone compounds, including two combination candidates for age-related diseases.

Aptuit prefers to operate behind the scenes. A pharmaceutical services company, Aptuit offers a range of support services to biotech and other drug development companies, including early- to late-stage development of pharmaceutical ingredients, clinical studies support, information systems development, project management, and consulting services. The company operates from more than a dozen offices in North America, Europe, and the Asia-Pacific region and serves companies of all sizes. Aptuit was founded in 2004; private equity firm Welsh, Carson, Anderson & Stowe holds a significant ownership stake in the company.

Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel. Pluristem Therapeutics Inc., a development stage bio-therapeutics company, engages in the research, development, and production of placental-derived adherent stromal cells (ASCs). The company also involves in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of various severe degenerative, ischemic, and autoimmune disorders. It develops a pipeline of products that are derived from the human placenta, a non-controversial, non-embryonic, and adult stem cell source. These placental adherent stromal cells (ASCs) are expanded in the company’s proprietary PluriX three-dimensional bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. The company’s principal product under Phase I clinical trial is PLX-PAD for people suffering from peripheral artery disease. Its pre-clinical products include PLX-IBD for inflammatory bowel diseases; PLX-STROKE for ischemic strokes; PLX-BMT for bone marrow transplantation; and PLX-MS for multiple sclerosis. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007.

Rowett Research Services (RRS) will supply the technology, thanks to its research parent, the Rowett Institute. It will even throw in marketing services and project management. All RRS needs are companies interested in commercializing new ideas and products. Its primary focuses are nutrition issues and outpatient health care studies, such as antimicrobial agents and antioxidants. Founded in 1988, RRS works with public and private partners in the pharmaceutical, biotechnology, food, and agricultural industries to bring the research underway at the Rowett Institute to the marketplace.

Amphastar Pharmaceuticals, Inc. is a generic and specialty pharmaceutical company that is engaged in the discovery, development, manufacture and marketing of generic and proprietary pharmaceuticals, innovative delivery systems and active pharmaceutical ingredients. Amphastar’s Management Team takes pride in the Company’s “3H” commitment to "High Quality, High Efficiency and High Technology". In keeping with this pledge of excellence to the consumer, Amphastar will continue to invest in state-of-the-art equipment, research & development, facilities, and the advancement of their employees.

Columbia Laboratories, Inc. company was founded in 1986 and is based in Livingston, New Jersey. Columbia Laboratories, Inc. engages in the research, development, and commercialization of women's healthcare and endocrinology products. Its products are used to treat infertility, endometriosis, dysmenorrhea, preterm birth for women with a short cervix at mid-pregnancy, and hormonal deficiencies. The company's products primarily utilize its patented Bioadhesive Delivery System technology. The company markets vaginal progesterone gel products to assist women who are infertile become pregnant in the United States, which include CRINONE 8% for technical procedures to reproductive endocrinologists; PROCHIEVE 8% to obstetricians and gynecologists; and PROCHIEVE 4% for treatment of secondary amenorrhea. It also provides vaginal gel women's products, such as Replens, a vaginal moisturizer for replenishment of vaginal moisture; RepHresh vaginal gel that eliminates vaginal odor; and Advantage-S, a female contraceptive gel. In addition, the company offers STRIANT, a testosterone buccal system for the treatment of hypogonadism in men; and Advance Formula Legatrin PM for the relief of occasional pain and sleeplessness associated with minor muscle aches. Further, it engages in clinical development activities of vaginally-administered lidocaine to prevent and treat dysmenorrhea, as well as vaginally-administered carbamide peroxide for treating vaginal infections; and testosterone progressive hydration vaginal tablet for women, which completed phase I trial.

Hollis-Eden Pharmaceuticals, Inc. company was founded in 1992 and is headquartered in San Diego, California. Hollis-Eden Pharmaceuticals Inc., a development stage pharmaceutical company, engages in the discovery and development of products for the treatment of diseases and disorders, in which the body is unable to mount immune or metabolic response due to disease or the process of aging. The company focuses on developing a series of adrenal steroid hormones and hormone analogs that are derived from its Hormonal Signaling Technology Platform. It develops two clinical drug development candidates, TRIOLEX (HE3286), which is in initial clinical trials for the treatment of type 2 diabetes, ulcerative colitis, and rheumatoid arthritis; and APOPTONE (HE3235) that is in a clinical trial for late-stage prostate cancer. The company is also exploring APOPTONE for other cancers, such as breast cancer. In addition, Hollis-Eden Pharmaceuticals has a research program that is generating clinical leads for evaluation in preclinical models of various diseases, including metabolic and autoimmune conditions, as well as inflammatory diseases of the lung, bone metabolism, and regenerative medicine.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.